These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19048778)

  • 21. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
    Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB
    Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.
    Pottier G; Marie S; Goutal S; Auvity S; Peyronneau MA; Stute S; Boisgard R; Dollé F; Buvat I; Caillé F; Tournier N
    J Nucl Med; 2016 Feb; 57(2):309-14. PubMed ID: 26585058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
    Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
    Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.
    Batrakova EV; Li S; Miller DW; Kabanov AV
    Pharm Res; 1999 Sep; 16(9):1366-72. PubMed ID: 10496651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceramide 1-Phosphate Increases P-Glycoprotein Transport Activity at the Blood-Brain Barrier via Prostaglandin E2 Signaling.
    Mesev EV; Miller DS; Cannon RE
    Mol Pharmacol; 2017 Apr; 91(4):373-382. PubMed ID: 28119480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development.
    Ohtsuki S; Terasaki T
    Pharm Res; 2007 Sep; 24(9):1745-58. PubMed ID: 17619998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
    Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
    Tournier N; Valette H; Peyronneau MA; Saba W; Goutal S; Kuhnast B; Dollé F; Scherrmann JM; Cisternino S; Bottlaender M
    J Nucl Med; 2011 Mar; 52(3):415-23. PubMed ID: 21321274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
    Cascorbi I; Haenisch S
    Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells.
    Sakata S; Fujiwara M; Ohtsuka K; Kamma H; Nagane M; Sakamoto A; Fujioka Y
    Oncol Rep; 2011 Feb; 25(2):333-9. PubMed ID: 21165575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse.
    Vautier S; Lacomblez L; Chacun H; Picard V; Gimenez F; Farinotti R; Fernandez C
    Eur J Pharm Sci; 2006 Feb; 27(2-3):167-74. PubMed ID: 16263252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Demystifying brain penetration in central nervous system drug discovery. Miniperspective.
    Di L; Rong H; Feng B
    J Med Chem; 2013 Jan; 56(1):2-12. PubMed ID: 23075026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug delivery via the blood-brain barrier.
    Edwards RH
    Nat Neurosci; 2001 Mar; 4(3):221-2. PubMed ID: 11224531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.